Activators & Inhibitors

C6 NBD Ceramide is a cell-permeable Golgi fluorescent probe (Ex=466 nm, Em=536 nm), a neuraminidic acid with a green fluorescent tag that can recognize Golgi apparatus in live and fixed cells, observing morphological changes of the Golgi apparatus in live cells. C6 NBD Ceramide can be metabolized intracellularly to generate fluorescent sphingomyelin and glucosylceramide, thus applied in studies of sphingolipid transport and metabolism mechanisms.

C6 NBD Glucosylceramide, a fluorescent derivative of glucosylceramide (Ex=466 nm, Em=535 nm), is utilized to investigate glucosylceramide metabolism and internalization, as well as to assess glucosylceramide synthase activity [1] [2] [3].

NUC-7738 is a 5'-aryloxyphosphoamidate prodrug of 3'-dA that reduces β-catenin nuclear expression in AML cells, modulates β-catenin signaling, and can be used in cancer research.

VK-1727, a selective small molecule inhibitor of EBNA1, diminishes the DNA binding activity of EBNA1 and curtails the proliferation and metabolic activity of EBV+ cells while not affecting EBV- cells. This compound is utilized in research pertaining to multiple sclerosis [1].

Glutathione ethyl ester TFA is a glutathione substitute and a cell-permeable glutathione GSH donor that modulates age-related oxidative damage in bovine oocytes, improves the developmental capacity of oocytes from aged cows, and prevents early asthma.

Nrf2-IN-3 is a mKEAP1-selective NRF2 inhibitor that selectively binds KEAP1 mutants and restores their NRF2 inhibitory function by repairing the disrupted KEAP1/NRF2 interaction, and selectively sensitizes cisplatin in xenografts of mouse mKEAP1 cancer cells.

Monlunabant ((S)-MRI-1891), a solid dispersion compound, functions as an inhibitor of the cannabinoid CB1 receptor [1].

β-Patchoulene, a tricyclic sesquiterpene extracted from Pogostemon cablin (patchouli oil), has potential therapeutic applications in the treatment of inflammatory diseases [1].

Zigakibart (BION-1301) is a humanized monoclonal antibody of the IgG4-kappa subtype, targeting TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256), and exhibits anti-inflammatory activity [1].